Stay updated on MBG453 Combo with Azacitidine & Venetoclax Clinical Trial
Sign up to get notified when there's something new on the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page.

Latest updates to the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page
- Check2 days agoChange DetectedA site-wide notice about potential delays due to a lapse in government funding and NIH Clinical Center status was added, and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check9 days agoChange DetectedGlossary toggle added and color-coded change highlights (green for additions, red for deletions) with a new revision label (v3.4.0). Older No FEAR Act data entry and revision v3.3.4 were removed.SummaryDifference0.5%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedLatest revision v3.3.4 (2026-01-13) adds Adverse Events, Participant Flow, References, Contacts/Locations, and Study Status to the record, while the previous revision v3.3.3 was removed.SummaryDifference0.5%

- Check44 days agoChange DetectedThe history page adds a new entry 'Revision: v3.3.3' and removes the footer items 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision from v3.2.0 to v3.3.2 is reflected on the page; no study data or page content is affected.SummaryDifference0.1%

- Check80 days agoChange DetectedNovartis decided to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following negative results from two other trials. The history also removes a government-funding notice and records that the study was terminated due to negative results across the program.SummaryDifference0.8%

Stay in the know with updates to MBG453 Combo with Azacitidine & Venetoclax Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page.